Research ExplorerPublicationsInhalative and intravenous stimulation of soluble guanylate ...

Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock

Standard

Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock. / Kronas, Nils; Peters, Birte; Richter, Hans Peter; Goetz, Alwin Eduard; Kubitz, Jens Christian.

In: EXP THER MED, Vol. 13, No. 4, 04.2017, p. 1369-1375.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kronas, N, Peters, B, Richter, HP, Goetz, AE & Kubitz, JC 2017, 'Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock', EXP THER MED, vol. 13, no. 4, pp. 1369-1375. https://doi.org/10.3892/etm.2017.4149

APA

Kronas, N., Peters, B., Richter, H. P., Goetz, A. E., & Kubitz, J. C. (2017). Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock. EXP THER MED, 13(4), 1369-1375. https://doi.org/10.3892/etm.2017.4149

Vancouver

Kronas N, Peters B, Richter HP, Goetz AE, Kubitz JC. Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock. EXP THER MED. 2017 Apr;13(4):1369-1375. https://doi.org/10.3892/etm.2017.4149

Bibtex

@article{c3bdc632bd1c42e78de4373150068c3c,
title = "Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock",
abstract = "The effects of inhaled and intravenous application of a guanylate cyclase stimulator (BAY 41-8543) on pulmonary vascular resistance (PVR) and cardiac output (CO) were investigated in an experimental model of septic shock. Following induction of septic shock, anaesthetized pigs (n=31) were randomly place into two groups receiving different interventions. Animals in the first group received intravenous BAY 41-8543 (0.6 mg), inhalative BAY 41-8543 (6 mg) or a placebo. In the second group, the dosage of BAY 41-8543 was increased two-fold or combined with inhalation of nitric oxide (iNO). Intravenous and inhaled administration of BAY 41-8543 resulted in a significantly (P<0.05) reduced PVR and increased CO compared with the placebo. Increasing the dosage of BAY 41-8543 or combining it with iNO did not further decrease PVR. The results of the present study indicate that BAY 41-8543 effectively reduces PVR and increases CO in septic shock, through inhaled or intravenous routes of administration.",
author = "Nils Kronas and Birte Peters and Richter, {Hans Peter} and Goetz, {Alwin Eduard} and Kubitz, {Jens Christian}",
year = "2017",
month = apr,
doi = "10.3892/etm.2017.4149",
language = "English",
volume = "13",
pages = "1369--1375",
journal = "EXP THER MED",
issn = "1792-0981",
publisher = "SPANDIDOS PUBL LTD",
number = "4",

}

RIS

TY - JOUR

T1 - Inhalative and intravenous stimulation of soluble guanylate cyclase reduces pulmonary vascular resistance and increases cardiac output in experimental septic shock

AU - Kronas, Nils

AU - Peters, Birte

AU - Richter, Hans Peter

AU - Goetz, Alwin Eduard

AU - Kubitz, Jens Christian

PY - 2017/4

Y1 - 2017/4

N2 - The effects of inhaled and intravenous application of a guanylate cyclase stimulator (BAY 41-8543) on pulmonary vascular resistance (PVR) and cardiac output (CO) were investigated in an experimental model of septic shock. Following induction of septic shock, anaesthetized pigs (n=31) were randomly place into two groups receiving different interventions. Animals in the first group received intravenous BAY 41-8543 (0.6 mg), inhalative BAY 41-8543 (6 mg) or a placebo. In the second group, the dosage of BAY 41-8543 was increased two-fold or combined with inhalation of nitric oxide (iNO). Intravenous and inhaled administration of BAY 41-8543 resulted in a significantly (P<0.05) reduced PVR and increased CO compared with the placebo. Increasing the dosage of BAY 41-8543 or combining it with iNO did not further decrease PVR. The results of the present study indicate that BAY 41-8543 effectively reduces PVR and increases CO in septic shock, through inhaled or intravenous routes of administration.

AB - The effects of inhaled and intravenous application of a guanylate cyclase stimulator (BAY 41-8543) on pulmonary vascular resistance (PVR) and cardiac output (CO) were investigated in an experimental model of septic shock. Following induction of septic shock, anaesthetized pigs (n=31) were randomly place into two groups receiving different interventions. Animals in the first group received intravenous BAY 41-8543 (0.6 mg), inhalative BAY 41-8543 (6 mg) or a placebo. In the second group, the dosage of BAY 41-8543 was increased two-fold or combined with inhalation of nitric oxide (iNO). Intravenous and inhaled administration of BAY 41-8543 resulted in a significantly (P<0.05) reduced PVR and increased CO compared with the placebo. Increasing the dosage of BAY 41-8543 or combining it with iNO did not further decrease PVR. The results of the present study indicate that BAY 41-8543 effectively reduces PVR and increases CO in septic shock, through inhaled or intravenous routes of administration.

U2 - 10.3892/etm.2017.4149

DO - 10.3892/etm.2017.4149

M3 - SCORING: Journal article

C2 - 28413479

VL - 13

SP - 1369

EP - 1375

JO - EXP THER MED

JF - EXP THER MED

SN - 1792-0981

IS - 4

ER -